27th Apr 2022 07:00
Arecor Therapeutics plc
("Arecor" or the "Group")
Arecor to present on Investor Meet Company Platform
Cambridge, UK, 27 April 2022: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives, today announces that Sarah Howell, Chief Executive Officer and Susan Lowther, Chief Financial Officer will be providing a live presentation relating to the Group's recently announced Year End Results for the year ended 31 December 2021 via the Investor Meet Company platform, on Thursday 5 May 2022 at 10:00am BST.
The presentation is open to all existing and potential shareholders and will be followed by a Q&A session. Questions can be submitted ahead of the event through the Investor Meet Company dashboard until 9am BST on Wednesday 4 May, or at any time during the live presentation.
To sign up to Investor Meet Company for free and to register for Arecor's presentation, please visit: https://www.investormeetcompany.com/arecor-therapeutics-plc/register-investor. Investors who already follow Arecor on the Investor Meet Company platform will automatically be invited to the event.
-ENDS-
For more information, please contact:
Arecor Therapeutics plc | www.arecor.com |
Dr Sarah Howell, Chief Executive Officer | Tel: +44 (0) 1223 426060 Email: [email protected] |
Susan Lowther, Chief Financial Officer | Tel: +44 (0) 1223 426060 Email: [email protected] |
Mo Noonan, Communications | Tel: +44 (0) 7876 444977 Email: [email protected] |
Panmure Gordon (UK) Limited (NOMAD and Broker) Freddy Crossley, Emma Earl (Corporate Finance) Rupert Dearden (Corporate Broking) | Tel: +44 (0) 20 7886 2500
|
Consilium Strategic Communications | |
Chris Gardner, David Daley, Angela Gray | Tel: +44 (0) 20 3709 5700 Email: [email protected] |
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary formulation technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver enhanced formulations of their therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio.
For further details please see our website, www.arecor.com
Related Shares:
Arecor Therape